Key result
Mice lacking a functional ACE N-domain exhibited 53% less albuminuria than diabetic wild-type mice, indicating that blocking the ACE N-domain ameliorates diabetic kidney disease.
Why the study?
Does the absence of the ACE N-domain or C-domain reduce renal inflammation and injury in a mouse model of diabetic kidney disease?
Does the absence of the ACE N-domain or C-domain reduce renal inflammation and injury in a mouse model of diabetic kidney disease?
Blocking the ACE N-domain may ameliorate diabetic kidney disease by increasing AcSDKP and facilitating sodium excretion, independent of angiotensin II.
Answers are grounded in this paper and cite their sources.
ACE domains may modulate diabetic renal inflammation independently of Ang II; leaves open whether selective inhibition alters nephropathy progression.
BACKGROUND: Recent evidence emphasizes the critical role of inflammation in the development of diabetic nephropathy. Angiotensin-converting enzyme (ACE) plays an active role in regulating the renal inflammatory response associated with diabetes. Studies have also shown that ACE has roles in inflammation and the immune response that are independent of angiotensin II. ACE's two catalytically independent domains, the N- and C-domains, can process a variety of substrates other than angiotensin I. METHODS: To examine the relative contributions of each ACE domain to the sodium retentive state, renal inflammation, and renal injury associated with diabetic kidney disease, we used streptozotocin to induce diabetes in wild-type mice and in genetic mouse models lacking either a functional ACE N-domain (NKO mice) or C-domain (CKO mice). This protective phenotype was not associated with changes in renal angiotensin II levels. Further, we present evidence that the anti-inflammatory tetrapeptide N-acetyl-seryl-asparyl-lysyl-proline (AcSDKP), an ACE N-domain-specific substrate that accumulates in the urine of NKO mice, mediates the beneficial effects observed in the NKO. CONCLUSIONS: These data indicate that increasing AcSDKP by blocking the ACE N-domain facilitates sodium excretion and ameliorates diabetic kidney disease independent of intrarenal angiotensin II regulation.
No takes yet. Share an insight, caveat, or question.
Eriguchi et al. (2018) studied Diabetic kidney disease. Absence of functional ACE N-domain (NKO mice) vs. Diabetic wild-type mice was evaluated on Albuminuria (53% less albuminuria). Mice lacking a functional ACE N-domain exhibited 53% less albuminuria than diabetic wild-type mice, indicating that blocking the ACE N-domain ameliorates diabetic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: